Pregnancy and breastfeeding in women with multiple sclerosis
Nervenarzt. 2024 Feb 23. doi: 10.1007/s00115-024-01621-9. Online ahead of print.ABSTRACTThe diagnosis of multiple sclerosis (MS) in women of reproductive age is associated with many uncertainties regarding childbearing and lactation. Pregnancies of MS patients are not usually considered high-risk pregnancies per se. The likelihood of pregnancy complications or adverse pregnancy outcomes is not increased by the disease; however, a careful planning of pregnancy is important in order to choose the treatment option with the greatest benefit for the mother and the least possible risk for the baby. For highly active courses of t...
Source: Der Nervenarzt - February 23, 2024 Category: Neurology Authors: Laura Witt Sandra Thiel Kerstin Hellwig Source Type: research
Pregnancy and breastfeeding in women with multiple sclerosis
Nervenarzt. 2024 Feb 23. doi: 10.1007/s00115-024-01621-9. Online ahead of print.ABSTRACTThe diagnosis of multiple sclerosis (MS) in women of reproductive age is associated with many uncertainties regarding childbearing and lactation. Pregnancies of MS patients are not usually considered high-risk pregnancies per se. The likelihood of pregnancy complications or adverse pregnancy outcomes is not increased by the disease; however, a careful planning of pregnancy is important in order to choose the treatment option with the greatest benefit for the mother and the least possible risk for the baby. For highly active courses of t...
Source: Der Nervenarzt - February 23, 2024 Category: Neurology Authors: Laura Witt Sandra Thiel Kerstin Hellwig Source Type: research
Effects of High Efficacy Multiple Sclerosis Disease Modifying Drugs on the Immune Synapse: A Systematic Review
CONCLUSION: The puzzle of HEDMD effects on the immune synapse is far from complete. The available evidence suggests that distinguishing differences exist between drugs and are worth pursuing further.PMID:38343058 | DOI:10.2174/0113816128288102240131053205 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - February 12, 2024 Category: Drugs & Pharmacology Authors: Spyros N Deftereos George D Vavougios Christos Bakirtzis George Hadjigeorgiou Nikolaos Grigoriadis Source Type: research
Natalizumab extended interval dosing: What about wearing-off effect?
This study aimed to evaluate the impact of EID in WO in MS patients under natalizumab. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - February 10, 2024 Category: Neurology Authors: Catarina Bernardes, Catarina Fernandes, Carolina Cunha, Carla Nunes, Carmo Mac ário, Lívia Sousa, Sónia Batista, Inês Correia Source Type: research
Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis
ConclusionsA higher risk of drug-related PML in patients whose immune system is not additionally depressed by means of neoplasms, HIV or concomitant medications is found in the neurological field. This risk is higher in MS treatment, and specifically during long-term natalizumab therapy. While this drug is still routinely prescribed in this field, considering the efficacy in reducing MS relapses, in other areas it could play a smaller role, and be gradually replaced by other safer and more recently approved agents. (Source: Drug Safety)
Source: Drug Safety - February 7, 2024 Category: Drugs & Pharmacology Source Type: research
Natalizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - February 1, 2024 Category: Drugs & Pharmacology Source Type: research
Visualizing the target estimand in comparative effectiveness studies with multiple treatments
Conclusion: Visualization tools may help to clarify the target population in comparative effectiveness studies and resolve ambiguity about the interpretation of estimated treatment effects.PMID:38261336 | PMC:PMC10842272 | DOI:10.57264/cer-2023-0089 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - January 23, 2024 Category: General Medicine Authors: Gabrielle Simoneau Marian Mitroiu Thomas Pa Debray Wei Wei Stan Rw Wijn Joana Caldas Magalh ães Justin Bohn Changyu Shen Fabio Pellegrini Carl de Moor Source Type: research
Analysis of seroconversion following COVID-19 vaccination among multiple sclerosis patients treated with disease-modifying therapies in Poland
CONCLUSIONS AND CLINICAL IMPLICATIONS: Our study shows that, in PwMS receiving immunomodulatory therapy, the immune response to vaccination is generally excellent. Even in immunosuppressive patients, seroconversion is satisfactory.PMID:38251955 | DOI:10.5603/pjnns.96425 (Source: Neurologia i Neurochirurgia Polska)
Source: Neurologia i Neurochirurgia Polska - January 22, 2024 Category: Neurology Authors: Aleksandra Podlecka-Pi ętowska Janusz Sierdzi ński Monika Nojszewska Jakub Stawicki Halina Bartosik-Psujek Beata Lech Ma łgorzata Popiel Adam Perenc Alina Ku łakowska Agata Czarnowska Joanna Kulikowska Katarzyna Kapica-Topczewska Anna Jamr óz-Wiśnie Source Type: research
Plasma antioxidant potential measured by total radical trapping antioxidant parameter in a cohort of multiple sclerosis patients
ConclusionOur findings suggest that lower plasma antioxidant potential is linked to more severe disability measured by EDSS scores. Patients treated with NTZ and FTY had reduced antioxidant power, which might be influenced by the active MS disease rather than the treatments themselves. The study reveals a strong positive correlation between UA levels and TRAP, particularly among women. However, men on average had better antioxidant potential than women. Neither the disease type nor the duration influences TRAP levels. While serving as a marker of antioxidant potential, plasma TRAP in MS patients does not reliably reflect o...
Source: Brain and Behavior - January 18, 2024 Category: Neurology Authors: Marge Kartau,
Joonas Kartau,
Marjatta Pohja,
Auli Verkkoniemi ‐Ahola Tags: ORIGINAL ARTICLE Source Type: research
Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis
Conclusion
In active MS, an early postpartum treatment strategy should be determined well before delivery. Natalizumab/fingolimod-strategy reduced postpartum relapse hazard from month 3, but none diminished the early postpartum relapse hazard. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - January 11, 2024 Category: Neurosurgery Authors: Haben, S., Ciplea, A. I., Tokic, M., Timmesfeld, N., Thiel, S., Gold, R., Langer-Gould, A. M., Hellwig, K. Tags: JNNP Patients' choice, Open access Multiple sclerosis Source Type: research
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are als...
Source: Cochrane Database of Systematic Reviews - January 4, 2024 Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
CONCLUSIONS: We are highly confident that, compared to placebo, two-year treatment with natalizumab, cladribine, or alemtuzumab decreases relapses more than with other DMTs. We are moderately confident that a two-year treatment with natalizumab may slow disability progression. Compared to those on placebo, people with RRMS treated with most of the assessed DMTs showed a higher frequency of treatment discontinuation due to AEs: we are moderately confident that this could happen with fingolimod, teriflunomide, interferon beta-1a, laquinimod, natalizumab and daclizumab, while our certainty with other DMTs is lower. We are als...
Source: Cochrane Database of Systematic Reviews - January 4, 2024 Category: General Medicine Authors: Marien Gonzalez-Lorenzo Ben Ridley Silvia Minozzi Cinzia Del Giovane Guy Peryer Thomas Piggott Matteo Foschi Graziella Filippini Irene Tramacere Elisa Baldin Francesco Nonino Source Type: research
Varicella Zoster Associated Vasculopathy and Retinitis with Natalizumab Use in Multiple Sclerosis
We present a case of combined CNS varicella zoster vasculitis and acute retinal necrosis in a 57-year-old woman maintained on monthly Natalizumab therapy, who presented with headache and visual field deficits.PMID:38166073 (Source: Herpes)
Source: Herpes - January 2, 2024 Category: Infectious Diseases Authors: Erika L Thayer Syed A Rizvi Glenn A Tung Source Type: research
Varicella Zoster Associated Vasculopathy and Retinitis with Natalizumab Use in Multiple Sclerosis
We present a case of combined CNS varicella zoster vasculitis and acute retinal necrosis in a 57-year-old woman maintained on monthly Natalizumab therapy, who presented with headache and visual field deficits.PMID:38166073 (Source: Herpes)
Source: Herpes - January 2, 2024 Category: Infectious Diseases Authors: Erika L Thayer Syed A Rizvi Glenn A Tung Source Type: research
